A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features.

Autor: Klughammer J; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA. klughammer@genzentrum.lmu.de.; Gene Center and Department of Biochemistry, Ludwig Maximilians Universität München, Munich, Germany. klughammer@genzentrum.lmu.de., Abravanel DL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. daniel_abravanel@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. daniel_abravanel@dfci.harvard.edu., Segerstolpe Å; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA., Blosser TR; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA., Goltsev Y; Baxter Laboratory in Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA., Cui Y; Department of Media Arts and Sciences, McGovern Institute, Massachusetts Institute of Technology, Cambridge, MA, USA., Goodwin DR; Department of Media Arts and Sciences, McGovern Institute, Massachusetts Institute of Technology, Cambridge, MA, USA., Sinha A; Department of Media Arts and Sciences, McGovern Institute, Massachusetts Institute of Technology, Cambridge, MA, USA., Ashenberg O; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA., Slyper M; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA., Vigneau S; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Jané-Valbuena J; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA., Alon S; Department of Media Arts and Sciences, McGovern Institute, Massachusetts Institute of Technology, Cambridge, MA, USA.; Faculty of Engineering, Gonda Brain Research Center and Institute of Nanotechnology, Bar-Ilan University, Ramat Gan, Israel., Caraccio C; Baxter Laboratory in Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA., Chen J; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Cohen O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Guiron University, Beersheba, Israel., Cullen N; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., DelloStritto LK; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Dionne D; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA., Files J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Frangieh A; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Helvie K; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Hughes ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Inga S; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Kanodia A; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Lako A; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., MacKichan C; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Mages S; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Gene Center and Department of Biochemistry, Ludwig Maximilians Universität München, Munich, Germany., Moriel N; School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem, Israel., Murray E; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Napolitano S; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Nguyen K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Nitzan M; School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem, Israel.; Racah Institute of Physics, The Hebrew University of Jerusalem, Jerusalem, Israel.; Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel., Ortiz R; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Patel M; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Pfaff KL; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Porter CBM; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA., Rotem A; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA.; AstraZeneca R&D, Boston, MA, USA., Strauss S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Strasser R; Gene Center and Department of Biochemistry, Ludwig Maximilians Universität München, Munich, Germany., Thorner AR; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Turner M; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA, USA., Wakiro I; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Waldman J; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA., Wu J; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Gómez Tejeda Zañudo J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Zhang D; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Winer EP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Boyden ES; Department of Media Arts and Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA.; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.; K. Lisa Yang Center for Bionics, Massachusetts Institute of Technology, Cambridge, MA, USA., Chen F; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA., Nolan GP; Baxter Laboratory in Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA., Rodig SJ; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Department of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Zhuang X; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA.; Department of Physics, Harvard University, Cambridge, MA, USA., Rozenblatt-Rosen O; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Genentech, Inc., South San Francisco, CA, USA., Johnson BE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Regev A; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA. regev.aviv@gene.com.; Genentech, Inc., South San Francisco, CA, USA. regev.aviv@gene.com., Wagle N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. wagle.nikhil@gene.com.; Harvard Medical School, Boston, MA, USA. wagle.nikhil@gene.com.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA. wagle.nikhil@gene.com.; Broad Institute of Harvard and MIT, Cambridge, MA, USA. wagle.nikhil@gene.com.; Genentech, Inc., South San Francisco, CA, USA. wagle.nikhil@gene.com.

Publikováno v: Nature medicine [Nat Med] 2024 Nov; Vol. 30 (11), pp. 3236-3249. Date of Electronic Publication: 2024 Oct 30.

Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.

Autor: Gómez Tejeda Zañudo J; Cancer Program, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Barroso-Sousa R; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Oncology Center, Hospital Sírio-Libanês, Brasília, Brazil., Jain E; Cancer Program, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Repare Therapeutics, Cambridge, MA, USA., Jin Q; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, MA, USA., Li T; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, MA, USA., Buendia-Buendia JE; Cancer Program, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cellarity, Somerville, MA, USA., Pereslete A; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Abravanel DL; Cancer Program, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Ferreira AR; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal., Wrabel E; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Helvie K; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hughes ME; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Overmoyer B; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Lin NU; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Tayob N; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, MA, USA., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Wagle N; Cancer Program, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, USA. Nikhil_Wagle@dfci.harvard.edu.; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Nikhil_Wagle@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. Nikhil_Wagle@dfci.harvard.edu.; Genentech, South San Francisco, CA, USA. Nikhil_Wagle@dfci.harvard.edu.

Publikováno v: Nature communications [Nat Commun] 2024 Mar 19; Vol. 15 (1), pp. 2446. Date of Electronic Publication: 2024 Mar 19.

A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.

Autor: Balch SM; The Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1259, Boston, MA, 02215, USA., Vaz-Luis I; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1259, Boston, MA, 02215, USA.; Institut Gustave Roussy, Unit INSERM 981, Villejuif, France., Li T; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Tayob N; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Jain E; The Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1259, Boston, MA, 02215, USA., Helvie K; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1259, Boston, MA, 02215, USA., Buendia-Buendia JE; The Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Cellarity, Inc., Cambridge, MA, USA., Shannon E; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Isakoff SJ; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Tung NM; Harvard Medical School, Boston, MA, USA.; Beth Israel Deaconess Medical Center, Boston, MA, USA., Krop IE; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1259, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1259, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA., Wagle N; The Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1259, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA., Freedman RA; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1259, Boston, MA, 02215, USA. rafreedman@partners.org.; Harvard Medical School, Boston, MA, USA. rafreedman@partners.org.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2021 Sep; Vol. 189 (2), pp. 411-423. Date of Electronic Publication: 2021 Jul 24.

Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems.

Autor: Alon S; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA.; McGovern Institute, MIT, Cambridge, MA, USA.; Faculty of Engineering, Gonda Brain Research Center and Institute of Nanotechnology, Bar-Ilan University, Ramat Gan, Israel., Goodwin DR; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA.; McGovern Institute, MIT, Cambridge, MA, USA., Sinha A; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA.; McGovern Institute, MIT, Cambridge, MA, USA.; Harvard-MIT Program in Health Sciences and Technology, MIT, Cambridge, MA, USA., Wassie AT; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA.; McGovern Institute, MIT, Cambridge, MA, USA.; Department of Biological Engineering, MIT, Cambridge, MA, USA., Chen F; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Daugharthy ER; Department of Genetics, Harvard Medical School, Boston, MA, USA.; Wyss Institute for Biologically Inspired Engineering, Boston, MA, USA., Bando Y; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA.; Kioxia Corporation, Minato-ku, Tokyo, Japan., Kajita A; Fixstars Solutions Inc, Irvine, CA, USA., Xue AG; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA., Marrett K; Fixstars Solutions Inc, Irvine, CA, USA., Prior R; Fixstars Solutions Inc, Irvine, CA, USA., Cui Y; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA.; McGovern Institute, MIT, Cambridge, MA, USA., Payne AC; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Yao CC; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Suk HJ; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA.; McGovern Institute, MIT, Cambridge, MA, USA.; Harvard-MIT Program in Health Sciences and Technology, MIT, Cambridge, MA, USA., Wang R; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA.; McGovern Institute, MIT, Cambridge, MA, USA., Yu CJ; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA.; McGovern Institute, MIT, Cambridge, MA, USA.; Department of Biological Engineering, MIT, Cambridge, MA, USA., Tillberg P; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA., Reginato P; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA.; Department of Biological Engineering, MIT, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Genetics, Harvard Medical School, Boston, MA, USA.; Wyss Institute for Biologically Inspired Engineering, Boston, MA, USA., Pak N; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA.; McGovern Institute, MIT, Cambridge, MA, USA.; Department of Mechanical Engineering, MIT, Cambridge, MA, USA., Liu S; Department of Genetics, Harvard Medical School, Boston, MA, USA.; Wyss Institute for Biologically Inspired Engineering, Boston, MA, USA., Punthambaker S; Department of Genetics, Harvard Medical School, Boston, MA, USA.; Wyss Institute for Biologically Inspired Engineering, Boston, MA, USA., Iyer EPR; Wyss Institute for Biologically Inspired Engineering, Boston, MA, USA., Kohman RE; Department of Genetics, Harvard Medical School, Boston, MA, USA.; Wyss Institute for Biologically Inspired Engineering, Boston, MA, USA., Miller JA; Allen Institute for Brain Science, Seattle, WA, USA., Lein ES; Allen Institute for Brain Science, Seattle, WA, USA., Lako A; Center for Immuno-Oncology (CIO), Dana-Farber Cancer Institute, Boston, MA, USA., Cullen N; Center for Immuno-Oncology (CIO), Dana-Farber Cancer Institute, Boston, MA, USA., Rodig S; Center for Immuno-Oncology (CIO), Dana-Farber Cancer Institute, Boston, MA, USA., Helvie K; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Abravanel DL; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Cell Biology, Harvard Medical School, Boston, MA, USA., Wagle N; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Johnson BE; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Klughammer J; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Slyper M; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Waldman J; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Jané-Valbuena J; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Rozenblatt-Rosen O; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Regev A; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Koch Institute for Integrative Cancer Research, Department of Biology, MIT, Cambridge, MA, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA., Church GM; Department of Genetics, Harvard Medical School, Boston, MA, USA. gchurch@genetics.med.harvard.edu edboyden@mit.edu.; Wyss Institute for Biologically Inspired Engineering, Boston, MA, USA., Marblestone AH; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA., Boyden ES; Department of Media Arts and Sciences, MIT, Cambridge, MA, USA. gchurch@genetics.med.harvard.edu edboyden@mit.edu.; McGovern Institute, MIT, Cambridge, MA, USA.; Department of Biological Engineering, MIT, Cambridge, MA, USA.; Koch Institute for Integrative Cancer Research, Department of Biology, MIT, Cambridge, MA, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA.; Department of Brain and Cognitive Sciences, MIT, Cambridge, MA, USA.

Publikováno v: Science (New York, N.Y.) [Science] 2021 Jan 29; Vol. 371 (6528).

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.

Autor: Wander SA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Cohen O; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Gong X; Eli Lilly and Co., Indianapolis, Indiana., Johnson GN; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Buendia-Buendia JE; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Lloyd MR; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Kim D; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Luo F; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Mao P; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Helvie K; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Kowalski KJ; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Nayar U; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Waks AG; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Parsons SH; Eli Lilly and Co., Indianapolis, Indiana., Martinez R; Eli Lilly and Co., Indianapolis, Indiana., Litchfield LM; Eli Lilly and Co., Indianapolis, Indiana., Ye XS; Eli Lilly and Co., Indianapolis, Indiana., Yu C; Eli Lilly and Co., Indianapolis, Indiana., Jansen VM; Eli Lilly and Co., Indianapolis, Indiana., Stille JR; Eli Lilly and Co., Indianapolis, Indiana., Smith PS; Eli Lilly and Co., Indianapolis, Indiana., Oakley GJ; Eli Lilly and Co., Indianapolis, Indiana., Chu QS; Cross Cancer Institute, Alberta, Canada., Batist G; Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Canada., Hughes ME; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Kremer JD; Eli Lilly and Co., Indianapolis, Indiana., Garraway LA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Eli Lilly and Co., Indianapolis, Indiana., Winer EP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Buchanan SG; Eli Lilly and Co., Indianapolis, Indiana., Wagle N; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts. nikhil_wagle@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

Publikováno v: Cancer discovery [Cancer Discov] 2020 Aug; Vol. 10 (8), pp. 1174-1193. Date of Electronic Publication: 2020 May 13.